Clovis Oncology Announces Second Quarter 2017 Operating Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- FOMC minutes from July 28-29th meeting
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
Clovis Oncology (CLVS) Posts Smaller Q2 Loss, Sales Beat
August 2, 2017 4:32 PM EDTClovis Oncology (NASDAQ: CLVS) reported Q2 EPS of ($1.29), $0.84 better than the analyst estimate of ($2.13). Revenue for the quarter came in at $14.62 million versus the consensus estimate of $13.31 million.
For earnings history and earnings-related data on Clovis Oncology (CLVS) click here.
... More